Hengrui Pharmaceutical announced that the company recently received a notice from the State Drug Administration that injectable rimazolam toluene sulfonate has been approved for additional indications for sedation during mechanical ventilation during intensive care. The drug has previously been approved domestically for sedation and anesthesia during non-tracheal intubation surgery/operation, and induction and maintenance of general anesthesia.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.